The human estrogen receptor α dimer binds a single SRC-1 coactivator molecule with an affinity dictated by agonist structure Nuclear receptors act as ligand-inducible transcription factors. Agonist binding leads to interaction with coactivator proteins, and to the assembly of the general transcription machinery. In addition to structural information, a thorough understanding of transcriptional activation by the nuclear receptors requires the characterization of the thermodynamic parameters governing these protein/protein interactions. In this study we have quantitatively characterized the interactions of full-length baculovirus expressed human estrogen receptor a (ERa), as well as ERa hormone binding domain (ERHBD) with a fragment of the coactivator protein SRC-1 (amino acid residues 570 to 780). Fluorescence anisotropy and¯uorescence correlation spectroscopy of¯uorescently labeled SRC-1 570-780 demonstrate unambiguously that the stoichiometry of the SRC-1/ERa/estradiol complex is one coactivator molecule per ERa dimer. The af®nity of the estradiol or estriol bound ERa/SRC-1 complexes was found to be signi®cantly higher than that observed in the presence of estrone. No binding was observed in the absence of ligand or in the presence of antagonists. Distinct anisotropy values for the ERa-SRC-1 complexes with different agonists suggest distinct conformations of the complexes depending upon agonist structure.
Introduction
Hormonal regulation of gene activity is mediated in part by nuclear receptors acting as ligand-activated transcription factors (Mangelsdorf et al., 1995) . These proteins interact with the ligand, the DNA-response element and, in an agonistdependant manner, with several proteins acting as transcriptional coactivators, such as CBP/p300, and the p160 family proteins (SRC-1, TIF-2, and SRC-3) (Robyr et al., 2000) . These protein/protein interactions are mediated by means of two activation functions (AFs), AF-1 located in the N-terminal region of the receptor, and AF-2 located in the hormone-binding domain. The crystal structures of the ligand-binding domains of several NR (reviewed by Moras & Gronemeyer, 1998) have shown the structural role of helix 12 in the active/ inactive switching of the AF-2. In the agonist bound complexes, H12 creates a hydrophobic groove recognized by the coactivator and in contrast, in the antagonist bound complexes, H12 is displaced outward, disrupting this interaction surface.
Speci®c motifs in the coactivators with the consensus sequence LXXLL called NR-boxes, are the dominant factors in modulating their binding to the NR, as shown by mutational mapping studies, yeast two-hybrid, and GST-pull down interaction experiments (Ding et al., 1998; Feng et al., 1998; Heery et al., 1997; Le Douarin et al., 1996; Mak et al., 1999) . SRC-1a contains four NR-boxes. Three of these (NR-boxes 1-3) are located near the center of the protein, and the fourth, which is lacking in TIF-2, is found in the C-terminal extremity (Heery et al., 1997; Kalkhoven et al., 1998) . Disruption of NR-box 2 has the most profound effect on interaction with ERHBD (Mak et al., 1999) .
Mutational studies on the NR-boxes (Tremblay et al., 1999; Voegel et al., 1998) , allosteric effects between heterodimers Westin et al., 1998) , as well as ligand dissociation kinetics (Gee et al., 1999) , suggest a stoichiometry of one coactivator per nuclear receptor dimer. On the other hand, Leers et al. (1998) suggest that two TIF-2 molecules could be present on a RXR/TR heterodimer using electrophoretic mobility shift assays. Two structures of complexes between agonist-bound NR ligand-binding domains and NR-box peptides have been solved by X-ray diffraction, in which each HBD monomer is bound by a coactivator derived peptide (Darimont et al., 1998; Shiau et al., 1998) . In addition, a complex between PPARg HBD and a 88 amino acid residue polypeptide comprising the NR-boxes 1 and 2 from SRC-1 shows each of the two NR-box interacting domains lying in the hydrophobic groove of each HBD monomer . This argues for a one SRC/NR dimer stoichiometry, although the rest of the SRC-1 molecule is not resolved in the structure.
Despite these studies, no direct determination of the stoichiometry of the NR/coactivator complexes has been carried out in solution under equilibrium conditions. Nor has SRC-1 and NR concentration dependence of the stoichiometry been ascertained. Af®nities for NR/coactivators interactions between 1 nM and 770 nM have been estimated from nonequilibrium or relatively indirect methods (Biacore (Suen et al., 1998) , antibody-mediated¯uorescence energy transfer (Zhou et al., 1998) , and ligand dissociation kinetics (Gee et al., 1999) ). Here, we have determined unambiguously the stoichiometry of the complexes between SRC-1 570-780 and ERHBD or full length ERa over a broad range of concentrations using¯uorescence correlation spectroscopy, while¯uorescence anisotropy-based titrations were used to determine the af®nity of the complexes. We also address the modulation of the interaction energies of these complexes by antagonists and by the three naturally occurring estrogens, i.e. 17-b estradiol and two of its metabolites:estrone and estriol.
Results
Ligand-dependent in vitro interaction of GST-SRC-1 with ERE-bound ERa a a
To study the interaction of SRC-1 with ERa bound to DNA, we ®rst used a modi®ed version of the GST-pull-down assay using GST-SRC-1, ERa expressed in COS cells and a 32 P-labeled oligonucleotide containing a consensus ERE. Binding of the labeled ERE to GST-SRC-1 was receptormediated since no speci®c binding was observed using mock transfected COS cell extracts (not shown). Formation of the ERE/ERa/SRC-1 ternary complex increased (more than 20-fold) in the presence of E2 (Figure 1(a) ). The EC 50 (0.4 nM) corresponded to the af®nity of the ligand for the receptor previously described by Anstead et al. (1997) .
Binding was speci®c for ERa agonists since ERE retention of the ERa:ERE complex onto GST-SRC-1 was observed with natural or synthetic estrogens but not in the presence of various antagonists such as 4-hydroxy-tamoxifen, raloxifen or ICI 182780 (Figure 1(b) ). However, it should be noted, as previously reported for the binding of ERa to hTIF1a, Figure 1 . In vitro interaction of GST-SRC-1 with EREbound ERa. (a) Ligand-dependent interaction of GST-SRC-1 with ERa bound onto DNA. The effect of increasing concentrations of E2 (pM to mM) on the interaction of GST-SRC-1 with ERa in the presence of 32 P-labeled ERE was analyzed as described in Material and Methods. Ternary complex formation was measured by b counting or by gel electrophoresis and detection using a Phosphorimager (inset). (b) Ligand speci®city of the interaction. Binding was analyzed as in (a) in the absence of ligand (C) or in the presence of 1 mM E2, E3, E1, OHT, Raloxifen (RAL) or ICI 182 780 (ICI). Similar amounts of GST-SRC-1 fusion protein were used as judged by Coomassie blue staining of the gel prior tō uorography. Results represent mean of three determinations AE SD.
that E2 was the most potent ligand in inducing the interaction whereas estrone exhibited a lower ef®-ciency (The Ânot et al., 1999) .
Characterization of SRC-1/Estrogen Receptor binding with an Alexa488 labeled SRC-1
The interaction of SRC-1 570-780 with ERa and ERHBD was next monitored by measuring changes in the steady state¯uorescence anisotropy of a¯u-orescent probe (Alexa 488) covalently coupled to the N terminus of the SRC-1 fragment ( A488 SRC-1). The anisotropy value is the intensity normalized difference between vertically and horizontally polarized¯uorescence emission and is inversely proportional to the rotational diffusion, thus the larger the molecule, the higher the anisotropy (Lakowicz, 1991) .
Interaction between A488 SRC-1 and ERHBD or full length ERa is observed as an increase in anisotropy only in the presence of the ERa agonists, but not in the absence of hormone, or in the presence of ERa antagonists (Ral, OH-Tam) (Figure 2 (a) and (b)). Moreover, this interaction is reversed by the addition of excess unlabeled SRC-1, which competes for receptor binding (Figure 2 (a) and (b)). Identical titration results for SRC-1 labeled with Alexa 568, which differs from Alexa 488 by two additional aromatics rings (Panchuk-Voloshina et al., 1999) , demonstrated that the nature of the probe does not in¯uence the binding (data not shown). As in a previous work with TIF-1a (The Ânot et al., 1999) , titration of a¯uorescein-labeled ERE/ERa complex with SRC-1 also revealed an agonist-dependent increase in anisotropy, whereas no change was observed in the absence of ligand or in the presence of antagonist (data not shown).
Determination of the stoichiometry of the SRC-1/ER interaction

Oligomeric state of the ERa
Quantitative analysis of anisotropy binding pro®les for the ER/SRC-1 interaction require the unambiguous determination of the ®nal stoichiometry of the complex. First, the oligomeric state of the ERa (full-length and HBD) was characterized in the micromolar concentration range. Quasi elastic light scattering experiments yielded an apparent diameter of 7.5 nm in the absence and presence of estradiol, corresponding to molecular mass values of 60 and 64(AE12) kDa, consistent in both cases with a dimer. Cooperative anisotropybased DNA binding pro®les for full length ERa are indicative of a dimerization constant near 10 nM (Boyer et al., 2000) .
Stoichiometric titration
Stoichiometric titrations of A488 SRC-1 by ERHBD were performed and the increase in the¯uor-escence anisotropy of the labeled SRC-1 was measured. Unlabeled SRC-1 was used at a concentration of 880 nM (greater than tenfold K D for the E2-induced interaction, see below), in the presence of a low concentration of labeled A488 SRC-1 (5 nM) and titrated by ERHBD (Figure 3 ) in the presence of E2. The anisotropy value is observed to continue to increase well beyond a ratio of one ERHBD monomer per SRC-1 molecule, supporting the hypothesis that the complex stoichiometry is likely two ERHBD monomers/SRC-1. In addition to the stoichiometric titration, a number of other¯uor-escence-based approaches (data not shown) provided support for the hypothesis that only one SRC-1 fragment is present in complexes with ERa dimers. A¯uorescence energy transfer experiment, using A488 SRC-1 (50 nM) as a donor and A568 SRC-1 (50 nM) as acceptor (R 0 60 A Ê ) revealed no detectable FRET upon addition of ERHBD and E2. Moreover, in the presence of saturating ERHBD and E2, addition of an anti-Alexa 488 antibody lead to a further increase in the anisotropy of A488 SRC-1 whereas no anisotropy supershift was observed for the A568 SRC-1 anisotropy. Finally, in a variation of a classical GST-pull down experiment, no¯uor-escence from A488 SRC-1 was detected upon mixing with SRC-1-GST proteins loaded on Sepharose beads in the presence of ERa and E2 under conditions of complex formation.
Fluorescence correlation spectroscopy
Although these experiments strongly support a stoichiometry of one SRC-1 molecule per ERa dimer, we sought to perform a direct measure of complex stoichiometry using¯uorescence correlation spectroscopy (FCS) with photon counting histogram (PCH) analysis. In an FCS experiment, the distribution of photon counts emanating from ER/SRC-1 Interactions a small excitation volume (achieved by two-photon excitation in an inverted microscope with a high numerical aperture objective) is described by the individual molecular brightness of the¯uorescent molecules and their concentrations (Chen et al., 1999a,b) . For example, proteins with either one or two dye labels can be successfully resolved by a single measurement (Muller et al., 2000) .
FCS experiments were performed as described in Materials and Methods using a high nominal concentration of A488 SRC-1 (200 nM) in order to favor a putative 2:1 SRC-1:ERa dimer complex. We note that the concentration of A488 SRC-1 was found by FCS to be threefold lower than the nominal concentration based on the Lowry method. This low value was subsequently shown to be due to loss of the SRC1 molecules which adhere to the walls of the LabTek chamber, since we observed a decrease of intensity with time, which can be recovered by mixing the solution. Repetition of the experiments yielded the correct nominal concentration shortly after pipetting the sample, but this value tended to decrease with time. We note that this phenomenon only occurs in the FCS experiments due to the nature of the chamber, and did not occur for measurements using glass tubes, i.e. the¯uor-escence anisotropy experiments. We also note that the molecular brightness value from which we deduce the stoichiometry is an absolute value and does not depend upon the concentration of¯uoro-phore.
PCH analysis of the photon count distributions (Figure 4 ) obtained for SRC-1 alone and with increasing concentrations of ERa (up to 105 nM dimer) in the presence of estradiol ®t well to a single species model with a molecular brightness value of 42,600 (AE300) cpsm (counts per second and molecule) and a global reduced w 2 of 1.2 (Table 1 ). This brightness value corresponds to that of a single Alexa 488 molecule. Dilution of A488 SRC-1 alone over a concentration range of 150 nM to 9 nM A488 SRC-1 yielded a constant value for the molecular brightness (data not shown), demonstrating that no association/dissociation process for the A488 SRC-1 occurs over this concentration range. Since the labeling ratio was determined to be one dye molecule/SRC-1 molecule (see Materials and Methods), and the molecular brightness observed corresponds to that of free Alexa 488, we conclude that A488 SRC-1 is monomeric under these conditions. The fact that the molecular brightness value of the monomeric A488 SRC-1 does not increase upon addition of ERa indicates that SRC-1 is present as a monomer in the complexes with ERa under these conditions. An observed decrease in the diffusion coef®cient of the A488 SRC-1 from 90 to 50 mm 2 s À1 upon addition of ERa, as well as¯uorescence anisotropy measurements carried out in parallel con®rm that binding of the A488 SRC-1 to the ERa did indeed occur. Moreover, neither the¯uorescence intensity of A488 SRC-1, nor its¯uorescence lifetime decreased upon titration with ERHBD or fulllength ERa, ruling out the masking of the existence of a 2:1 SRC-1/ER complex through quenching by homotransfer.
Simulations of fractional complex populations
In order to reach an unambiguous conclusion as to the stoichiometry of SRC-1 complexes with ERa, it is necessary to demonstrate that a putative 2:1 complex would have been populated under the conditions tested, and detected with the FCS. In accordance, we have carried out simulations of the fractional population of the 1:1 and 2:1 complexes under different conditions. First, we assumed the presence of two binding sites of equal intrinsic af®-nity for SRC-1 on the ERa dimer. Since the apparent dissociation constant for the interaction between SRC-1 and ERa dimer estimated from the binding curves (see below) is 30 nM, for the case of two identical binding sites, due to the statistical entropy term, the intrinsic dissociation constant would be 60 nM. In this case, at 70 nM SRC-1 (concentration estimated from the FCS experiments due to loss of protein through adhesion), the 2:1 species would be maximally populated at a level of 9 % at 105 nM ERa dimer. However, this model considers SRC-1 as a monovalent ligand. A more realistic model (arising from the structure of the PPAR/SRC-1 complex ) takes into account the fact that a single SRC-1 molecule can bind both monomers of the ERa dimer, since the SRC-1 fragment contains three LXXLL motifs. In this case, there is no difference in the entropy contribution to the statistics for binding the ®rst and second SRC-1 molecules, and thus the intrinsic and statistical dissociation constants are equal (30 nM). According to this model we would expect the 2:1 species to be populated at a level of 25 % at 70 nM SRC-1 and 105 nM ERa dimer.
In order to reject the hypothesis of this 2:1 species being present we re-analyzed the FCS data at 105 nM ERa and 70 nM SRC-1 (histogram from Figure 4 (d)) assuming the same brightness for the 1:1 species and the free A488 SRC-1 and a doubling of the brightness for the 2:1 species (no change in uorescence intensity is observed upon binding). The error analysis shows, that as little as 6 % of the putative 2:1 complex would have been detected with a con®dence level of 99.7 %. However, although all our models predict signi®cantly higher populations of the 2:1 species than our lower detection limit of 6 %, this species is not detected by the analysis. Therefore, we conclude that only one SRC-1 molecule is present in its complexes with Table 1 . The upper panels shows the PCH raw data and the ®t, and the lower panels are a plot of the residuals.
ER/SRC-1 Interactions
ERa under all of our experimental conditions. If a complex involving two SRC-1 molecules can be populated under conditions of very high SRC-1 concentration, the af®nity for binding the second SRC-1 molecule to the ERa dimer must be signi®-cantly lower than that for binding the ®rst (at least a tenfold decrease in af®nity).
Finally, we also rule out the possibility that one SRC-1 molecule binds two ERa dimers. If a complex containing two ERa dimers and a single SRC-1 monomer were populated, due to the large difference in molecular weight compared to a complex containing only one ERa dimer, one would expect to observe a much larger change in anisotropy in the equilibrium titrations (see below Figure 5 , which involve high ratios of ER HBD/ SRC-1, up to 50-fold) as compared to the stoichiometric titrations (Figure 3 , in which this ratio did not exceed threefold). However, the total anisotropy change (35 milli-anisotropy units) upon titration of A488 SRC-1 is identical regardless of the total concentration of SRC-1 (and thus the ratio of ER HBD/SRC-1). Thus we conclude that one SRC-1 molecule and one ERa dimer are present in the complex which predominates under all concentration conditions tested.
Modulation of the SRC-1/ER affinity by ligands and response elements
The af®nities of A488 SRC-1 for ERHBD, fulllength ERa, and full length ERa in the presence of saturating ERE oligonucleotide were determined from anisotropy-based titrations of the A488 SRC-1 (Figure 5(a)-(c) ). These binding pro®les were ®t using a simple model based on the stoichiometry of (SRC-1) 1 /ER dimer (Table 2) . FCS experiments using A488 SRC-1, ERHBD and ERa at the low concentrations of SRC-1 (5 nM) used in the titrations con®rmed this stoichiometry in the presence of all agonists. The af®nity of A488 SRC-1 for ERHBD in the presence of E2 is quite high (K D 30 nM) and is similar for full length ERa, indicating that no additional interaction with this fragment of SRC-1 is conferred by the presence of the AF1 domain. The af®nity of the E2-bound ERa for A488 SRC-1 is approximately fourfold lower (K D 116 nM) in the presence of saturating ERE, indicating that DNA binding introduces mild energetic constraints against SRC-1 binding. We note that at concentrations greater than 5 nM ERa the receptor is fully bound to its ERE, and that the ER-ERE af®nity is independent of the state or type of ligation (Boyer et al., 2000) .
In all cases, E2 and E3 exhibited similar ef®cien-cies for promoting ER-SRC-1 complex formation (Table 2) , whereas E1 was two to threefold less ef®-cient, consistent with the PPDA experiments (Figure 1) . It is interesting that the ®nal anisotropy values obtained from the ®ts of the data in Figure 5 (b) and (c) for the A488 SRC-1/ERa complexes were signi®cantly lower in the presence of E1 and E3 compared to that observed in the 
Discussion
We have used a variety of approaches (most based on¯uorescence spectroscopy) to characterize the interaction of a fragment of the steroid receptor coactivator 1 with the full length human estrogen receptor a or its hormone binding domain. Fluorescence correlation experiments, together with classic steady state approaches, have allowed us to demonstrate unambiguously a stoichiometry of one SRC-1 molecule per ERa dimer (full length or isolated HBD) under all our experimental conditions. PCH analysis of the¯uorescence correlation data is a powerful tool for the determination of the stoichiometry of molecular complexes under single molecule conditions (Chen et al., 1999a; Muller et al., 2000) . Here, we show that this information can be exploited at higher concentrations, which makes it suitable for the investigation of a large number of biomolecular complexes, including those of modest af®nity. In fact, the characterization of the stoichiometry of biomolecular complexes can be one of the most dif®cult tasks in advancing our understanding of these interactions. A number of techniques are available but each presents its own advantages and disadvantages. For example, analytical ultracentrifugation provides very accurate estimations of molecular weight but requires relatively large concentrations (micromolar) and, for equilibrium measurements, several hours. In our case, the dif®culty in obtaining large quantities of the proteins involved and their marginal stability (especially in the case of full-length ERa) precluded the use of analytical ultracentrifugation, although for other applications, in particular, complexes of lower af®nity for which the material is not a limiting factor, it would be the technique of choice. PCH analysis on the other hand is very rapid, a few minutes, and requires very low concentrations and small volumes of material. In the present case, PCH analysis is also more accurate than measurement of the translational diffusion coef®cient by dynamic light scattering, analytical ultracentrifugation, correlation spectroscopy or rotational diffusion by timeresolved¯uorescence anisotropy. In fact, the difference in the molecular brightness for a 2:1 SRC-1/ ERa complex would be twofold compared to a 1:1 complex, whereas, the change in translational or rotational diffusion coef®cients would be marginal given the low molecular mass of the SRC-1 fragment compared to that of the ERa (a 1:1 complex has a molecular mass of 176 kDa, and a 2:1 complex only increases to 202 kDa).
It is noteworthy that binding of a single SRC-1 molecule to a symmetric ERa homodimer introduces an asymmetry in the complex, which may contribute to the proper orientation of the preinitiation complex. From this point of view, the estrogen receptor system resembles the homodimeric catabolite gene activator protein (CAP) for which activator ligand binding is anti-cooperative, and whose active functional subunit depends on the promoter architecture, thus leading to an alternate interaction mode with the RNA polymerase (Zhou et al., 1994) . In the presence of estradiol, the af®nity between SRC-1 and the ERHBD dimer is 30 nM, similar to previously reported results based on less direct methods (Gee et al., 1999; Zhou et al., 1998) , but signi®cantly lower than the 1 nM K D obtained using Biacore measurements on SRC-3 and ERa (Suen et al., 1998) . We also found that the af®nity of SRC-1 for full-length ERa is comparable to that for ERHBD. Therefore, it is unlikely that this fragment of SRC-1 presents additional interactions with the AF-1 domain of ERa. However, the decrease in af®nity between SRC-1 and fulllength ERa when bound to the ERE indicates that the DNA-binding domain and its interaction with the ERE alter the properties of the SRC-1 interactions with the HBD. Since many natural response elements for ERa are imperfect palindromes, the ER dimer may undergo asymmetric conformational changes, involving a preferential orientation of the coactivator molecule relative to the promoter. Uncertainties on the recovered dissociation constants were obtained by rigorous con®dence limit testing, which involves re®tting the curve at each tested value of the parameter.
ER/SRC-1 Interactions
Of particular interest is the observed modulation of the af®nity when estrone is used instead of estradiol, suggesting that the relative potency of different agonists could result from their relative ability to promote interaction between ERa and the coactivator proteins. The effects of the three natural estrogens E2, E1 and E3 (which differ in structure at only two positions (C 16 and C 17 )) on gene expression is not precisely correlated with their relative af®nity for ERa (®ve times lower for E1 and E3 compared to E2) (Anstead et al., 1997; Pilat et al., 1993) . We have observed previously modulation of receptor-coactivator af®nity by agonist structure in studies of the ERa/TIF-1a interaction (The Ânot et al., 1999) . Such modulation could re¯ect changes in the conformation of the receptor through an altered stabilization of helix 12 by E1 and E3. The lower plateau anisotropy values for the A488 SRC-1/ERa complexes in the presence of E1 or E3 relative to that observed in the presence of E2 do not arise from differences in stoichiometry as con®rmed by the FCS experiments, but rather are indicative of altered local dynamics of the Alexa probe in these different complexes. This difference in dynamics is only observed for complexes with the full-length ERa. Paige and co-workers (Paige et al., 1999) found that ERa and b may undergo distinct conformational changes depending upon the agonist used. Different conformations of the receptor could serve as well to promote a preferential interaction with speci®c coactivators, as is the case for the vitamin D receptor, which appears to exhibit a selective interaction with SRC-1 versus TIF-2, depending upon the agonist used (Takeyama et al., 1999) .
The crystal structures of NR hormone-binding domains in various ligation states (Darimont et al., 1998; Moras & Gronemeyer, 1998; Shiau et al., 1998) suggest that the repositioning of helix 12 upon agonist binding is crucial for the interaction with the coactivators. While antagonists clearly result in an unfavorable conformation of the helix 12 for coactivator binding, certain ligands could promote an intermediate or dynamic positioning of helix 12 leading to less ef®-cient interaction with the coactivators. It is clear that in addition to in vivo studies of hormone effects on cell growth and development, a thorough understanding of hormone-dependant transcriptional regulation will require the characterization of the subtle modi®cations by hormone of the structure, energetics and dynamics of the nuclear receptor/coactivator complexes.
Materials and Methods
E1, E2 and E3 were purchased from Sigma Aldrich (St Quentin, France), 4-hydroxy-tamoxifen (OHTAM) from Besins Iscovesco (Paris, France), and ICI 182780 (ICI) from AstraZeneca (London, UK). Raloxifen (Ral) was a kind gift from J.-C. Nicolas (INSERM U439, Montpellier, France).
Protein expression and purification
His-tagged proteins were over-expressed in Escherichia coli and puri®ed by Ni 2 -NTA agarose beads under native conditions (Quiagen, Courtaboeuf, France). DNA encoding the nuclear receptor interacting domain (NID, amino acid residues 570 to 780) was excised from pGex2tk-SRC-1 570-780 and subcloned into BamHI and SmaI digested pQE-30 (Quiagen) to generate the PQE 30 -SRC-1 570-780 plasmid. pET 15b -hERa encoded the HBD of hERa (K302-P552).
The expression and puri®cation of the GST-SRC-1 fusion protein was carried out as previously described by Cavailles et al. (1995) . The concentration of GST-SRC-1 loaded on the Sepharose beads was estimated by gel electrophoresis using ovalbumin and BSA as standards.
ERHBD concentration was determined by UV absorbance at 280 nm (e 24000 M À1 cm
À1
). SRC-1 concentration was determined by the Lowry method using BSA as a standard, due to the weak absorption of the polypeptide at 280 nm and interferences with the alexa dye in Bradford analysis. ERHBD activity was checked using [ 3 H]estradiol binding.
Full-length puri®ed baculovirus-expressed ERa was purchased from Panvera corp (Madison, WI). The concentration of active receptor in each preparation was determined by the supplier by tritiated estradiol binding and compared to the concentration of total protein obtained by Bradford analysis. All others preparations were over 90 % pure as assessed by SDS-PAGE.
Oligonucleotides
HPLC puri®ed oligonucleotides were purchased from Genosys (Cambridge, UK). The target sequence referred to here as ERE has the sequence given below for the sense strand: 5 H -AGCTTCGAGGAGGTCACA-GTGACCTGGAGCGGATC-3
H . The sense and anti-sense strands were annealed by heating to 85 C for ten minutes in 10 mM Tris buffer in the presence of 0.1 mM EDTA, 0.1 mM DTT (pH 7.5) and cooling slowly to room temperature. Proteins and oligonucleotides preparations were stored at À80 C.
Protein labeling
Alexa 488 and Alexa 568 protein labeling kits and Anti-Alexa 488 antibody were purchased from Molecular Probes (Eugene, OR), and labeling was performed as recommended by the supplier. Further puri®cation was performed by anion exchange HPLC to remove the remaining free¯uorophore and unlabeled protein.
Removal of free dye was veri®ed by thin layer chromatography. The labeling ratio was veri®ed as one¯uoro-phore/SRC-1 molecule by visible absorption and mass spectrometry.
Protein-protein-DNA assay (PPDA) PPDA binding assays were performed as described by The Ânot et al. (1999) using ERa expressing vector transfected COS cell extracts.
Fluorescence experiments
The buffer solution for all¯uorescence measurements was 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 10 % (v/v) glycerol (pH 7.5). Binding assays were performed using a Beacon 2000 polarization instrument regulated at 4 C, using ®lters for¯uorescein at a A488 SRC-1 concentration of 5 nM. Anisotropy was measured successively until stabilized, and the reported values are the average of ®ve to eight measurements after stabilization.
Fluorescence measurements on A568 SRC-1 were made using photon counting through a 590 nm high-pass ®lter on an ISS (Champaign, IL) Koala 2 with excitation at 550 nm. Binding data were analyzed using BIOEQS (Royer et al., 1990) .
For the¯uorescence¯uctuation experiments, a femtosecond mode locked Titanium-Sapphire laser (Mira 900, Coherent, Palo Alto, CA) set at 780 nm and pumped by an intracavity doubled Nd:YVO 4 laser (Coherent) was used as the two-photon excitation source. The experiments were carried out using a Zeiss Axiovert 135 TV microscope (Thornwood, NY) with a 63Â Plan Apochromat oil immersion objective (N.A. 1.4). The average power at the sample is less than 7 mW. No photobleaching was observed for any of the samples measured under our experimental conditions. Photon counts were detected with an avalanche photodiode (EG&G, SPCM-AG-151), directly connected to a home-built data acquisition card. The photon sampling frequency was set at 20 kHz. The photon counts were analyzed with programs written for PV-WAVE version 6.21 (Visuals Numerics, Houston, TX), described by Muller et al. (2000) .
